Fresenius SE, the diversified healthcare group from Germany, has identified possible firms for ripe for takeovers. The total cost of the potential buyouts would be at Eur300 million or US$389 million, according to Chief Executive Officer Ulf M. Schneider.
In an interview with German weekly newspaper Euro am Sonntag, "We are currently working on projects in the small and medium size range." This was the given response by the CEO to a question on whether the firm was on the watch for acquisitions that go outside the separate listing of its unit, Fresenius Medical Care.
According to Schneider, the deal would cost between Eur10 million and Eur20 million. He added that a mid sized deal could reach up to a payable by Fresenius of between Eur100 million and Eur300 million.
Schneider also said that the group's business profile would also change, with Fresenius Medical Care accounting between 20% and 30% of the overall profit of the group. The rise in the overall group profits would also come from earnings from other units of the group such as Helios, Kabi and Vamed.
Join the Conversation